Evidence map›Paper›PMID 37345881›Full record

ArticleCancer medicine2023

Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer.

Natalie Herold, Johanna Schmolling, Corinna Ernst, Beyhan Ataseven, Britta Blümcke, Birgid Schömig-Markiefka, Sebastian Heikaus, Uwe-Jochen Göhring, Christoph Engel, Björn Lampe and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. A Novel DNA Variant inInternational journal of molecular sciences · 2024
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Natalie HeroldCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-4493-5807
Johanna SchmollingCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Corinna ErnstCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-7756-8815
Beyhan AtasevenDepartment of Gynecology & Gynecologic Oncology, Kliniken Essen-Mitte (KEM), Essen, Germany.
Britta BlümckeCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Birgid Schömig-MarkiefkaInstitute of Pathology, University Hospital Cologne, Cologne, Germany.
Sebastian HeikausDepartment of Pathology, Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Uwe-Jochen GöhringDepartment of Gynecology and Obstetrics, Johanniter Krankenhaus, Bonn, Germany.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Björn LampeDepartment of Gynecology and Obstetrics, Diakonie Kaiserswerth, Düsseldorf, Germany.
Kerstin RhiemCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Philipp HarterDepartment of Gynecology & Gynecologic Oncology, Kliniken Essen-Mitte (KEM), Essen, Germany.
Jan HaukeCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-8236-4075
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Eric HahnenCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-1152-8367
University of Cologne · DEKliniken Essen-Mitte · DEDiakonie Deutschland · DEJohanniter-Krankenhaus Bonn · DEKlinikum Lippe · DELeipzig University · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Germ-Line MutationOvarian NeoplasmsDNA HelicasesFemaleGenetic Predisposition to DiseaseGerm CellsHumansNuclear ProteinsTranscription FactorsDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription FactorsBRCA mutationscancer risk factorsgynecological oncologyhereditary cancerovarian cancerSCCOHTSMARCA4

Identifiers

PMID37345881
PMCPMC10417158
OpenAlexW4381597571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.